Some have argued the House should focus on solving the pending ACA dispute through legislation, not litigation. Others argue the House is taking the best route available.
A deal that might have easily passed antitrust review a decade ago on account of its verticality may face greater skepticism these days from not only the DOJ and FTC but judges as well.
The proxy skirmish between a major healthcare player and an aspiring disruptor is headed to the First Circuit Court of Appeals, where judges will be asked to weigh in on whether an ex-Optum vice president should be blocked from starting his new job.
The administration outlined a strategy to target geographic "hot spots" and demographic groups at heightened risk of infection, without addressing expected costs.
The proposal would end safe-harbor protections for the rebates drug manufacturers pay to PBMs and add safe-harbor protections for drug discounts offered directly to patients.
